- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Menu
Menu
Menu
Menu
Menu
Brand Name :
Synonyms :
Class :
may have an increased QTc-prolonging effect when combined with amiodarone
may have an increased QTc-prolonging effect when combined with amiodarone
may have an increased QTc-prolonging effect when combined with amiodarone
may have an increased QTc-prolonging effect when combined with amiodarone
may have an increased QTc-prolonging effect when combined with amiodarone
It may enhance the effect when combined with lonafarnib by affecting CYP3A4 metabolism
It may diminish the bioavailability when combined with bile acid sequestrants
when both drugs are combined, there may be an increase in qtc interval
when both drugs are combined, there may be increased toxicity of amiodarone by QTC interval
when both drugs are combined, there may be an increase in the serum concentration of talazoparib
may increase the bradycardic effect
may decrease the therapeutic effect
may increase the QTc prolonging effect of QT-prolonging Class III Antiarrhythmics
It may enhance QTc interval when combined with pentamidine
may enhance the serum concentration when combined
It may enhance QTc interval when combined with perphenazine
It may enhance the effect when combined with pemigatinib by affecting CYP3A4 metabolism
it decreases the efficacy of sodium iodide I-131
when both drugs are combined, both increase the QTC interval
both lapatinib and amiodarone increase the QTc interval
may increase the QT-prolonging effect and enhance the risk of ventricular arrhythmias
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
CYP3A strong enhancers of the small intestine may reduce the the bioavailability of amiodarone
when both drugs are combined, there may be an increased QTc interval
amiodarone and gilteritinib, when used in combination, increase the QTc interval
when both drugs are combined, there may be an increase in the QTC interval
when both drugs are combined, there may be increase in ceritinib and arsenic trioxide both increase QTc interval
when both drugs are combined, there may be increase in ceritinib and arsenic trioxide both increase QTc interval
when both drugs are combined, there may be an increased risk of adverse effects
may increase the QTc interval when combined
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may enhance the serum concentration
may increase the QTc prolonging effect
may have an increased QTc-prolonging effect when combined with amiodarone
amiodarone may enhance the bradycardic effect of beta-blockers
amiodarone may enhance the bradycardic effect of beta-blockers
amiodarone may enhance the bradycardic effect of beta-blockers
amiodarone may enhance the bradycardic effect of beta-blockers
amiodarone may enhance the bradycardic effect of beta-blockers
may have an increased bradycardic effect when combined with beta-blockers
may have an increased bradycardic effect when combined with beta-blockers
may have an increased bradycardic effect when combined with beta-blockers
may have an increased bradycardic effect when combined with beta-blockers
may have an increased bradycardic effect when combined with beta-blockers
Strong CYP3A4 inducers may decrease serum concentrations of the active metabolite(s) of amiodarone
Strong CYP3A4 inducers may decrease serum concentrations of the active metabolite(s) of amiodarone
Strong CYP3A4 inducers may decrease serum concentrations of the active metabolite(s) of amiodarone
Strong CYP3A4 inducers may decrease serum concentrations of the active metabolite(s) of amiodarone
Strong CYP3A4 inducers may decrease serum concentrations of the active metabolite(s) of amiodarone
when both drugs combine amiodarone will increase effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
when both drugs are combined, there may be a decreased metabolism of etoposide
when both drugs are combined, there may be an increased risk of nerve damage
when both drugs are combined, there may be a reduced metabolism of erlotinib
increase the therapeutic effect of daunorubicin by P-glycoprotein efflux transporter
QTc interval are increased both by lenvatinib and amiodarone.
the effect of amiodarone is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
increases serum level of cabazitaxel by affecting the enzyme CYP3A4
May increase serum level and toxic effects of docetaxel by affecting MDR1/PG-P efflux transporter
when both drugs are combined, there may be an increased effect of ivosidenib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be an increased level or effect of amiodarone
when both drugs are combined, there may be an increased QTC interval
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
it enhances by affecting the hepatic enzyme CYP2C9 metabolism
relugolix/estradiol/norethindrone
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may enhance the serum concentration of CYP2C8 inhibitors
may increase the bradycardic effect of beta blockers
may increase the serum concentration of lidocaine
ADVERTISEMENT
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
USA – BOSTON
60 Roberts Drive, Suite 313
North Adams, MA 01247
INDIA – PUNE
7, Shree Krishna, 2nd Floor, Opp Kiosk Koffee, Shirole Lane, Off FC Road, Pune 411004, Maharashtra
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
MASSACHUSETTS – USA
60 Roberts Drive, Suite 313,
North Adams, MA 01247
MAHARASHTRA – INDIA
7, Shree Krishna, 2nd Floor,
Opp Kiosk Koffee,
Shirole Lane, Off FC Road,
Pune 411004, Maharashtra
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
